• The biggest minor news of the day (other than Lilly beating 1Q earnings…zzzz), is Discovery Labs. The Surfaxin developer has taken a fourth gut punch from the FDA. The agency is still not convinced with the surfactant’s CMC documentation and has requested quality control stability and release issues be resolved before they approve the treatment. Discovery has been trying to win approval since 2004. [FierceBiotech]

• Biogen says sixth patient on Tysabri gets brain infection. [WSJ]

• Ardea Biosciences announced positive results from a phase 1 study of RDEA594 and a phase 2a pilot study of RDEA806, both URAT1 inhibitors for the treatment of hyperuricemia and gout. [Yahoo!Finance]

• Peregrine Pharmaceuticals reported positive preliminary data from a phase 2 lung cancer trial of Bavituximab. [PR Newswire]

• What??!! No more pharma dinners in Massachusetts??!! [MedicalMeetings]

• Options for Acorda Therapeutics are smokin’ hot!!! [Forbes]

• Finally, Merck and Galapagos have signed a EUR 2.5M ($3.2M) drug discovery deal. [Hays Pharma]

Image from hotstocked

Related Posts